中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 10
Oct.  2011
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2011  >  27(10): 1093-1095+1098

Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma

  • Published Date: 2011-10-20
    Abstract
    • FullText(HTML)
  • loading
    • References(8)
  • [1]王志明, 周乐杜, 吕秀生, 等.原发性肝癌治疗方法的选择:附265例报告[J].中国普通外科杂志, 2004, 13 (12) :908-911.
    [2] 中华医学会肝病学会分会肝癌学组.原发性肝癌规范化诊治的专家共识[J], 内科理论与实践, 2009, 4 (4) :353-360.
    [3]Llovet JM, Bruix J.Molecular targeted therapies in hepato-cellular carcinoma[J].Hepatology, 2008, 48 (4) :1312-1327
    [4]郭武华, 张吉翔.肝癌综合治疗的现状[J].世界华人消化杂志, 2008, 16 (20) :2199-2203.
    [5]Llovet J, Ricci S, Mazzaferro V, et al.Sorafenib improvessurvival in advanced hepatocellular carcinoma (HCC) :Re-sults of a phase III randomized placebo-controlled trial (SHARP trial) [J].J Clin Oncol, 2007, 25:LBAl.
    [6]Liu L, Cao Y, Chen C, et al.Sorafenib blockes the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and in-duces tumor cell apoptosis in hepatocellular carcinoma modelPLC/PRF/5[J].Cancer Ras, 2006, 66 (24) :11851-11858.
    [7]Cheng AL, Kang YK, Chen Z, et al.Efficacy and safety ofsorafenib in patients in the Asia-Pacific region with ad-vanced hepatocellular carcinoma:a phase III randomized, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
    [8]Strumberg D, Awada A.Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced sol-id tumours:Is rash associated with treatment outcome?[J].Eur J Cancer, 2006, 42 (4) :548-556.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2405) PDF downloads(672) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return